Syndax Pharmaceuticals Inc
SNDXUS売上高
$172M
百万USD
営業利益
$-273M
百万USD
純利益
$-285M
百万USD
ROE
-441.6%
最新FY
EPS
$-3.29
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $0M | $-28M | - |
| FY2021 | Q2 | $0M | $-23M | - |
| FY2021 | Q3 | $12M | $-21M | - |
| FY2021 | FY | $140M | $25M | $0.46 |
| FY2022 | Q1 | $0M | $-37M | - |
| FY2022 | Q2 | $0M | $-38M | $-0.62 |
| FY2022 | Q3 | $12M | $-35M | $-0.58 |
| FY2022 | FY | $140M | $-149M | $-2.46 |
| FY2023 | Q1 | - | $-41M | $-0.59 |
| FY2023 | Q2 | - | $-45M | $-0.64 |
| FY2023 | Q3 | - | $-51M | $-0.73 |
| FY2023 | FY | $0M | $-209M | $-2.98 |
| FY2024 | Q1 | - | $-72M | $-0.85 |
| FY2024 | Q2 | $4M | $-68M | $-0.80 |
| FY2024 | Q3 | $13M | $-84M | $-0.98 |
| FY2024 | FY | $24M | $-319M | $-3.72 |
| FY2025 | Q1 | $20M | $-85M | $-0.98 |
| FY2025 | Q2 | $38M | $-72M | $-0.83 |
| FY2025 | Q3 | $46M | $-61M | $-0.70 |
| FY2025 | FY | $172M | $-285M | $-3.29 |
| FY2026 | Q1 | $65M | $-43M | $-0.48 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $2M | $2M | $2M | $140M | $140M | $0M | $24M | $172M |
| 営業利益 | $-44M | $-62M | $-76M | $-58M | $-71M | $26M | $-152M | $-230M | $-340M | $-273M |
| 純利益 | $-44M | $-61M | $-74M | $-56M | $-73M | $25M | $-149M | $-209M | $-319M | $-285M |
| 総資産 | $109M | $137M | $84M | $64M | $301M | $450M | $497M | $613M | $725M | $530M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $84M | $104M | $53M | $32M | $252M | $408M | $467M | $554M | $288M | $65M |
| 営業CF | - | - | $-69M | $-51M | $-71M | $29M | $-134M | $-161M | $-275M | $-323M |
| EPS | - | - | - | - | - | $0.46 | $-2.46 | $-2.98 | $-3.72 | $-3.29 |
| BPS | $4.61 | $4.22 | $2.12 | $1.04 | $5.23 | $7.42 | $6829.80 | $6.52 | $3.35 | $0.73 |
| ROE | -52.9% | -58.3% | -139.4% | -177.4% | -29.0% | 6.1% | -31.9% | -37.8% | -110.6% | -441.6% |